Clinical Observation of Tirofiban in the Treatment of Acute Progressive Cerebral Infarction
Objective To investigate the clinical efficacy of tirofiban in the treatment of acute progressive cerebral infarction.Methods 80 patients with acute progressive cerebral infarction admitted to Yingtan People's Hospital from June 2019 to June 2020 were selected and randomly divided into two groups,40 cases in each group.The control group was treated with clopidogrel and aspirin,and the observation group was treated with tirofiban based on the control group.The clinical efficacy,coagulation function,blood lipids,neurological function,liver and kidney function and adverse reactions were compared between the two groups.Results The clinical efficacy of the observation group was higher than that of the control group.After treatment,the thrombin time,prothrombin time,activated partial thromboplastin time of the observation group were higher than those of the control group,the D-Dimer was lower than that of the control group,and the National Institutes of Health Stroke Scale score was lower than that of the control group,with statistical difference(P<0.05).There was no statistical difference in blood lipid index,liver and kidney function and adverse reactions between the two groups(P>0.05).Conclusion Tirofiban has better effect in the treatment of patients with acute progressive cerebral infarction,can significantly improve the coagulation function and neurological function of patients,and has less damage to liver and kidney function,low incidence of adverse reactions,and good safety.
Acute progressive cerebral infarctionTirofibanClinical efficacyCoagulation functionNeurological function
万方数据
维普
